BG 00011
Alternative Names: BG-00011; STX-100Latest Information Update: 02 Oct 2021
At a glance
- Originator Biogen Idec
- Developer Biogen
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action Integrin alphaVbeta6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Idiopathic pulmonary fibrosis
Most Recent Events
- 05 Dec 2019 Discontinued - Phase-II for Idiopathic pulmonary fibrosis (In the elderly, In adults) in Germany, South Korea, United Kingdom, Spain, Russia, Poland, Netherlands, Italy, Israel, Greece, France, Denmark, Czech Republic, Chile, Belgium, Argentina, Australia and USA (SC) before December 2019 (Biogen pipeline, December 2019)
- 16 Sep 2019 Biogen terminates the phase II SPIRIT trial in Idiopathic pulmonary fibrosis (In the elderly, In adults) in USA, Argentina, Belgium, Chile, Czech Republic, Denmark, France, Greece, Israel, Italy, Netherlands, Poland, Russia, Spain, United Kingdom, South Korea, Germany (SC), due to safety concerns (NCT03573505)
- 17 May 2019 Efficacy data from a phase IIa trial in Idiopathic pulmonary fibrosis presented at the 115th International Conference of the American Thoracic Society (ATS-2019)